Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
Amivantamab plus lazertinib is approved for first-line management of EGFR-mutated advanced NSCLC.
Amivantamab plus lazertinib is approved for first-line management of EGFR-mutated advanced NSCLC. In MARIPOSA, amivantamab-lazertinib significantly improved overall survival versus osimertinib (hazard ratio [HR]: 0.75; p = 0.005). We evaluated acquired resistance mechanisms and their impact on second-line progression-free survival (PFS) in MARIPOSA.
Amivantamab-lazertinib reduces common resistance mechanisms (e.g., EGFRorMET) versus osimertinib, suggesting that this regimen is changing the underlying biology of EGFR‑mutant disease.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT